Formulation Development
Arch Scientists Publish Data on the Mechanism of Action & Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury
Arch Biopartners Inc. recently announced a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper…
Pharmazz Inc. Submits INDA to India Central Drugs Standard Control Organization for Phase 2 Clinical Trial of Sovateltide in Hypoxic-Ischemic Encephalopathy in Neonates
Pharmazz, Inc. recently announced it has submitted an Investigational New Drug Application (INDA) to the India Central Drugs Standard Control Organization (CDSCO) for a Phase…
Regio Biosciences Enters License Agreement With AstraZeneca for Phase 2a Asset in Peripheral Artery Disease
Regio Biosciences, a Hibiscus BioVentures company, recently announced it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic…
Silo Pharma Extends Exclusive Option Agreement for Homing Peptides
Silo Pharma, Inc. recently announced it has extended its exclusive option agreement with the University of Maryland, Baltimore, to explore a novel invention generally known as….
CordenPharma Completes Acquisition of Three Manufacturing Facilities From Vifor Pharma
CordenPharma recently announced the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. (including its…
Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis & Secures $175 Million Credit Facility
Tarsus Pharmaceuticals, Inc. recently announced it has completed enrollment of Saturn-2, the company’s second pivotal Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with….
Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune & Inflammatory Diseases from Carna Biosciences
Brickell Biotech, Inc. and Carna Biosciences, Inc. recently announced they have entered into a licensing agreement, whereby Brickell will have the exclusive, worldwide rights to develop and commercialize….
QSAM Biosciences Receives Rare Pediatric Disease Designation From FDA for CycloSam in the Treatment of Osteosarcoma
QSAM Biosciences Inc. recently announced the US FDA has granted Rare Pediatric Disease Designation to QSAM’s clinical-stage drug candidate, CycloSam, for the treatment osteosarcoma, a…
PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA in Advanced Head & Neck Cancer
PDS Biotechnology Corporation recently announced its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus (HPV)-associated head and neck cancer achieved its preliminary objective…
MaxCyte Signs Strategic Platform License With Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
MaxCyte, Inc. recently announced the signing of a strategic platform license (SPL) with Intima Bioscience, Inc., a clinical stage biotechnology company developing genetically engineered cell….
Polyplus Acquires e-Zyvec to Expand Expertise in Plasmid DNA Vector Engineering
Polyplus recently announced the acquisition of e-Zyvec, a provider of DNA design and production services for tailor-made DNA vectors for gene therapy, bio-manufacturing, and research.…
ANAVEX2-73 (Blarcamesine) AVATAR Phase 3 Trial Met Primary & Secondary Efficacy Endpoints for the Treatment of Adult Patients With Rett Syndrome
Anavex Life Sciences Corp. recently reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female….
Biogen Exercises Option to Participate in the Development & Commercialization of a Late-Stage Bispecific Antibody
Biogen Inc. recently announced it exercised its option to participate in the development and commercialization of mosunetuzumab. Biogen will pay a $30-million one-time option fee…
Biofrontera Inc. provides Update on Patient Recruitment for Phase 3 Study for the Treatment of sBCC With Ameluz-PDT
Biofrontera Inc. recently provided an update on the patient recruitment for the Phase 3 clinical study for the treatment of superficial basal cell carcinoma (sBCC)…
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals With Seborrheic Dermatitis
Arcutis Biotherapeutics, Inc. recently announced the enrollment of the last subject in its STRATUM Phase 3 pivotal trial for topical roflumilast foam in patients with….
Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
Skye Bioscience, Inc. recently announced that in a preclinical study assessing the neuroprotective properties of its SBI-100 ophthalmic nanoemulsion, the treated group demonstrated a trend…
Veru Enters Clinical Trial Collaboration & Supply Agreement With Eli Lilly & Company
Veru Inc. recently announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company. The objective of the collaboration is to evaluate the efficacy and safety of….
Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma
Aravive, Inc. recently announced it has dosed the first patient in the Phase 2 portion of the Phase 1b/2 study of batiraxcept for the treatment of clear cell renal cell carcinoma (ccRCC)…..
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity
Altimmune, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical trial of pemvidutide for…
Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next-Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Viridian Therapeutics, Inc. recently announced the US FDA clearance of its investigational new drug (IND) application of VRDN-002. The Company’s next generation IGF-1R antibody, VRDN-002,…
